Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
4 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
4
Trials led
4
Ongoing
2,316
Total enrollment
669
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 3
4
Trials by status
Recruiting
4
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)Age 55-90Ph 3Recruiting1,000
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)Alzheimer's diseasePh 3Recruiting500
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)Alzheimer's diseasePh 3Recruiting410
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)Alzheimer's diseasePh 3Recruiting406